In this review:
Olaparib plus abiraterone in mCRPC
AR-V7 status and response to abiraterone/enzalutamide in mCRPC
Accuracy of 68Ga-PSMA11 PET/ CT on recurrent prostate cancer
Adjuvant docetaxel and surveillance post radical radiotherapy for prostate cancer
KEYNOTE-199: Pembrolizumab for docetaxel-refractory mCRPC
PROSPECT: PROSTVAC-V/F vaccine for mCRPC
Abiraterone + prednisone vs enzalutamide as 2nd-line therapy in mCRPC
Genomic profiling of tumours from patients who develop mCRPC
Microsatellite instability and response to immune checkpoint blockade
Please login below to download this issue (PDF)